Document Detail

Bortezomib induces heme oxygenase-1 expression in multiple myeloma.
MedLine Citation:
PMID:  22617388     Owner:  NLM     Status:  MEDLINE    
Multiple myeloma (MM) is a progressive malignant disorder characterized by accumulation of plasma cells in the bone marrow. MM remains an incurable disease with a 5-y survival rate of approximately 40%. While clinical response rates to first line chemotherapeutics are high, disease relapse is inevitable, and occurs because a small fraction of the original myeloma cells appear to be resistant to treatment. Heme oxygenase-1 (HO-1) is an Nrf2 transcription factor-regulated gene that is commonly induced following oxidative stress and cellular injury, functioning to decrease oxidative stress and inflammatory responses, protecting against apoptosis and altering the cell cycle. We and others have highlighted the role of HO-1 in providing cellular protection against chemotherapeutic drugs in a number of cancer cells, which we have highlighted here in this Extra View. Furthermore, we explored the expression of HO-1 in multiple myeloma cells in response to the key anti-myeloma drugs bortezomib and lenalidomide. We show here for the first time that bortezomib increases HO-1 expression in a time- and concentration-dependent manner. Moreover, we also observe that HO-1 is increased in lenalidomide-resistant MM cell lines. Altogether, we highlight a possible role for HO-1 in basal and acquired chemoresistance in MM.
Lawrence N Barrera; Stuart A Rushworth; Kristian M Bowles; David J MacEwan
Related Documents :
18025308 - Cofilin determines the migration behavior and turning frequency of metastatic cancer ce...
15242648 - A role for drosophila iap1-mediated caspase inhibition in rac-dependent cell migration.
10910928 - Lsp1 modulates the locomotion of monocyte-differentiated u937 cells.
7968918 - Developmental decisions in dictyostelium discoideum.
9811758 - Rapid selection in modified bhk-21 cells of a foot-and-mouth disease virus variant show...
9000088 - Regulation of human endogenous retrovirus-k gag expression in teratocarcinoma cell line...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-06-15
Journal Detail:
Title:  Cell cycle (Georgetown, Tex.)     Volume:  11     ISSN:  1551-4005     ISO Abbreviation:  Cell Cycle     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-06-28     Completed Date:  2012-10-17     Revised Date:  2013-06-24    
Medline Journal Info:
Nlm Unique ID:  101137841     Medline TA:  Cell Cycle     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2248-52     Citation Subset:  IM    
School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology*,  therapeutic use
Apoptosis / drug effects
Boronic Acids / pharmacology*,  therapeutic use
Drug Resistance, Neoplasm / drug effects
Heme Oxygenase-1 / genetics,  metabolism*
Multiple Myeloma / drug therapy,  enzymology
Pyrazines / pharmacology*,  therapeutic use
Thalidomide / analogs & derivatives,  therapeutic use
Tumor Cells, Cultured
Reg. No./Substance:
0/Antineoplastic Agents; 0/Boronic Acids; 0/Pyrazines; 0/bortezomib; 191732-72-6/lenalidomide; 50-35-1/Thalidomide; EC Oxygenase-1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Selective blockade of tumor angiogenesis.
Next Document:  Why is F19Ap53 unable to bind MDM2?: Simulations suggest crack propagation modulates binding.